Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROWESS 15: Iloprost in PAH
NCT00709956Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2008
- Primary completion
- Aug 2009
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of iloprost in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: 6-minute-walk Distance at Day 3. Started Jul 2008; status: completed.
02
Drugs
iloprost
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00709956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00709956.